Update on PSMA-Directed Actinium Labeled Radioantibody Therapy
Time: 1:00 pm
day: Day Two ESC PM
Details:
- Exploring the rationale for using antibodies when targeting PSMA with Actinium-225
- Uncovering activity of CONV01-a monotherapy in advanced prostate cancer
- Sharing activity of CONV01- a combination therapies in advanced prostate cancer
